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erated a number of thoughts and reactions for me. The authors focus on several points, from a sustainable health system, to spending more on drugs, to lack of access to new efficacious drug therapies, to motives of government and to actions pharmacists and pharmacy organizations might take. During my career, I have served in a number of capacities, many of them related to the areas that were referenced in the article (community pharmacist, leader in provincial and national pharmacist organizations, public drug plan manager and in a senior role responsible for pan-Canadian programs on drug assessment and optimal drug use). It is with this background that I respectfully respond.
Let's begin with the sustainability of the health system. Year to year, decade to decade, we know the cost of our publicly funded and delivered Canadian health system is rising and that governments struggle to provide adequate funding. We know change and innovation are needed, and while there are ongoing efforts (e.g., provinces who move back and forth between central and regional delivery), it is complex and there is no magic solution. For those who might think the cost of drugs is being singled out, consider the provincial (pick almost any province over time) physician organizations that have struggled in negotiations or the hospital CEO who is faced with bed closures and staff shortages while demand for services increases. The issue is not whether a certain cost is 6% or 60% of the total but whether there are sufficiently improved health outcomes for the resources utilized. There is no single driver of rising costs. In addition, whether it be drugs or health technologies or surgical procedures, it is well known that more is not necessarily better (e.g., the Choose Wisely Campaign). It is also true that new is not necessarily better.
Publicly funded drug plans were put in place to cover drugs with evidence of benefit and to assist people with the costs of those drugs. Public drug plans are not perfect, nor are private plans. The debate on the lack of a National Pharmacare continues. I can say without reservation that in my decade of provincial drug plan management, there were no smoke screens, no listing decisions made with "no evidence" and there were efforts to remunerate pharmacists in new and innovative ways. Among the members of formulary committees/expert review committees are practising research and academic pharmacists. They work hard to review available evidence. Each recommendation is carefully considered before it is made. Members keep patients' needs in mind when they deliberate. They know that their recommendations have an impact on peoples' lives. They are caring professionals, and they serve selflessly and for the betterment of healthcare overall. It is no easy task.
Individual pharmacists, trusted and accessible, do well to serve their patients by understanding how drug plan decisions are made and to advocate on their patient's behalf. Learning about the information behind listing decisions is one step. Publicly funded drug plans are guided by the recommendations and reasons for recommendations for listing drugs by the Canadian Agency for Drugs and Technologies in Health. These have been publicly available since 2004. Pharmacists should familiarize themselves with available avenues to provide relevant evidence to request coverage under the drug plan. As trusted health practitioners, any comments pharmacists make to their patients will be valued and should be practical, constructive and evidence based. Patients expect it.
Pharmacy organizations are in the unique and privileged position of being able to give a larger, collective voice to the profession. The voice should be one of objectivity, of reliability, and above all, about improved health outcomes for patients. 
